Matthew Stroh, PhD is the Director and Medical Science Liaison for Neurology at Quest Diagnostics. Dr Stroh is an academically trained neuroscientist with expertise in complex neurodegenerative diseases, neuroimmunology, neuropsychiatry, and biomarkers associated with traumatic brain injury.
Dr Stroh obtained his Bachelor of Science in biochemistry from the University of Kansas. He then pursued a PhD in neuroscience from the University of Kansas School of Medicine, where he was awarded Honors for his dissertation. Following the completion of his doctoral degree, Dr Stroh went on to study contextual signaling in neurofibromatosis type 1 (NF1) at Washington University School of Medicine in St. Louis.
Prior to joining Quest, Dr Stroh worked in the pharmaceutical industry supporting the development and launch of treatments in various therapeutic areas, including migraine, nephrology, cardiology, Alzheimer’s disease, and rare developmental epileptic encephalopathies.
Dr Stroh’s current research interest focuses on the development of diagnostic approaches that drive personalized medicine in complex neurodegenerative disease. He has a long-standing interest in the role of tissue-specific susceptibility to pathogenic insult.
Dr Stroh is a member of various professional societies and organizations, including the American Academy of Neurology, Society for Neuroscience, and the Alzheimer’s Association.